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whis review includes articles published from July 2002 to
une 2003, with three exceptions.
ORTIC STENOSIS
ercutaneous transcatheter prosthetic heart valve (PHV)
nsertion. The first human implantation of an aortic PHV
as performed by the percutaneous transcatheter technique
1). This was a “last resort” procedure in a patient with
evere calcific aortic stenosis (AS) (aortic valve area [AVA]
.6 cm2; left ventricular ejection fraction [LVEF] 0.14),
ardiogenic shock, and a multitude of co-morbid condi-
ions. The PHV area was 1.6 cm2, and paravalvular aortic
egurgitation (AR) was mild. The patient died 17 weeks
ater from the associated co-morbid conditions (Fig. 1).
OMMENT. In humans, transcatheter PHV had been im-
lanted previously in the pulmonary position (2), and a
eport of a larger series is in press in JACC.
alcific AS: pathogenesis. A number of reports provided
vidence that the pathogenesis of AS is an active process
aving many similarities to atherosclerosis.
a) Rabbits fed a cholesterol diet by Rajamannan et al. (3)
revealed an increase of blood cholesterol and high
sensitive C-reactive protein (hsCRP) levels. Their
aortic valve (AV) showed increases of proliferation
cell nuclear antigen (PCNA), macrophages (RAM
11), and osteoblast bone markers [alkaline phospha-
tase, osteopontin, and osteoblast lineage-specific tran-
scription factor (Cbfa-1)], which were absent in the
control animals fed a normal diet. A third group of
animals fed a cholesterol diet plus atorvastatin had a
reduction of all the above markers except hsCRP
(Fig. 2).
b) These same investigators then examined stenotic AV
resected at time of aortic valve replacement (AVR)
and normal human AV removed at time of cardiac
transplantation (4). They documented the presence of
calcification and of CaPO4 in the AS valves. Reverse
transcriptase-polymerase chain reaction revealed in-
creased mRNA levels of osteopontin, bone sialopro-
tein, osteocalcin, and osteoblast-specific transcription
factor Cbfal in the calcified valves. They confirmed
their hypothesis, namely that AV calcification is not a
From the Division of Cardiovascular Medicine, Department of Medicine, LAC 
SC Medical Center, Keck School of Medicine, University of Southern California,
os Angeles, California.rManuscript received October 31, 2003; accepted December 3, 2003.random degenerative process but an active regulated
process associated with an osteoblast-like phenotype.
c) In another experimental study, the addition of vitamin
D2 to the cholesterol-enriched diet was necessary to
produce AS (5).
d) Studies of calcific AS identified high levels of TGF-1
in calcified valve nodules, which stimulated AV inter-
stitial cell in culture to aggregate, induce cellular
apoptosis, and calcify (6).
e) Patients who had AVR for severe AS when compared
to age- and gender-matched controls had higher
levels of lipoprotein (a), Chlamydia pneumoniae, IgG
antibody titers, high plasma leptin, and tissue-type
plasminogen activator mass concentration (7).
f) T-lymphocyte infiltration was present in tricuspid and
bicuspid AV without any significant difference in extent
and localization (8). Inflammation should be considered
in the pathogenesis of AS in both types of valves.
g) The suggested steps involved in the development of
calcific AS are summarized in Figure 3 (9).
OMMENT. The term “degenerative” as the etiology of
alcific AS needs to be abandoned.
ypertrophy and failure in AS: structural findings.
tructural abnormalities were studied in left ventricular
LV) myectomies from three groups of patients with severe
S undergoing AVR (group 1, LVEF 50%, n  12;
roup 2, LVEF 30% to 50%, n  12; group 3, LVEF
30%, n  10) and six control patients with mitral stenosis
MS) (group 4, LVEF 61 8%) (10). Myocyte hypertrophy
as accompanied by increased nuclear deoxyribonucleic acid
nd Sc-35 (splicing factor) content. In the three groups,
ngiotensin-converting enzyme (ACE) inhibitor and
GF-1 were up-regulated with fibrosis, which increased
y 2.3, 2.2, and 3.2 times over control; myocyte degenera-
ion increased by 10, 22, and 32 times over control (Fig. 4);
biquitin-related autophagic cell death was 0.5%, 1.05%,
nd 6.05%; death by oncosis was 3%, about 5%, and 4%,
espectively. Apoptosis was 0.2% in group 1, and 0.01% in
roup 2, but was not seen in groups 3 and 4. Cardiomyocyte
itosis was not observed. The investigators suggested a
odel of major adaptation to pressure overload (Fig. 5).
OMMENT. The r values of various correlations were only
.58, 0.57, and 0.65; it is possible that endocarditis (which
as the etiology in 65% of patients) and its duration had aole in the observed findings.
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The Year in Valvular Heart Disease February 4, 2004:491–504ssessment of severity. The calculation of energy loss
o-efficient (ELCO) by echocardiography/Doppler pro-
ided assessment of severity of AS, which was similar to that
btained by calculating AVA from data obtained at cardiac
atheterization (Fig. 6) (11). Table 1 shows the theoretical
oppler-derived AVA at different aortic cross-sectional
reas to “catheter-derived” AVA.
OMMENT. The best correlation is from patients who had
VAs 1.0 cm2 (Fig. 6); theoretically derived AVA needs
onfirmation in man (Table 1).
Another study compared various indices obtained from
chocardiography/Doppler assessments to patient out-
omes. The LV stroke work loss (LVSWL) was calculated
s AP (AP  SBP)  100, where AP was the mean aortic
radient and SBP (systolic blood pressure) were determined
igure 1. Percutaneous catheter implantation aortic valve replacement via th
rosthetic heart valve (PHV) but mild paravalvular regurgitation (arrow). L
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AR  aortic regurgitation
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve replacement
CAD  coronary artery disease
CBC  catheter balloon commissurotomy
CO  cardiac output
LA  left atrial/atrium
LV  left ventricular/ventricle
LVEF  left ventricular ejection fraction
LVSWL  left ventricular stroke work loss
MR  mitral regurgitation
MS  mitral stenosis
MVA  mitral valve area
MVrep  mitral valve repair
NYHA  New York Heart Association
OMC  open mitral commissurotomy
OR  odds ratio
PHV  prosthetic heart valve
PHVT  prosthetic heart valve thrombosis
SVD  structural valve deterioration
TEHV  tissue-engineered heart valve
V˙o2  body oxygen consumptionl., ref. 1.)n the echocardiographic laboratory (12). An LVSWL of
25% best discriminated clinical end points.
OMMENT. The concept of LVSWL as a parameter for
ssessment of severity of AS was conceived and developed
y John R. Tobin Jr. (13). It stated that the pressure-volume
ork lost in imparting kinetic energy to allow LV emptying
ad to relate to severity of AS and proved it to be correct
ith planimetered LV and aortic systolic pressures obtained
t cardiac catheterization. The present study has impor-
antly extended this observation to determine the relation-
hip of LVSWL to patient outcomes and to show it to be
etter than all the other parameters even though the
etermination of LVSWL was less than ideal.
pecific clinical syndromes. HEYDE’S SYNDROME. This
yndrome involves bleeding from gastrointestinal dysplasia
n patients with severe AS in whom bleeding usually ceases
fter AVR. Two women who had bleeding from endoscop-
cally proven dysplasia (14) had severe deficiency of high-
olecular-weight multimers of von Willebrand factor,
hich normalized postoperatively. Up to 10 years’ postop-
ration, neither patient had recurrent bleeding or anemia or
equired iron supplements.
VALUATION OF NITROPRUSSIDE IN CRITICALLY ILL PA-
IENTS. A total of 25 patients, mean age 73  15 years,
ith severe AS (AVA 1.0 cm2), LVEF 0.35, and
ardiac index 2.2 l/min/m2 received intravenous nitro-
russide in a dose titrated to produce a mean arterial
ressure between 60 and 70 mm Hg (15). The primary end
oint of the study was change from baseline in the cardiac
ndex during nitroprusside administration for 24 h. At 24 h,
he cardiac index had increased from 1.60  0.35 to 2.52 
.55 l/min/m2. However, mean arterial pressure also de-
reased from 81 to 69 and mean pulmonary artery (PA)
edge pressure fell from 27 to only 23. All patients
ontinued to receive nitroprusside until conversion to con-
entional medical therapy, death, or surgery (in some
atients many days later). The AVR was performed in 21
atients (one died), coronary artery bypass graft (CABG)
septal route. Aortogram in right panel shows no aortic regurgitation from
 left coronary artery; RCA  right coronary artery. (From Cribier A, ete tran
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February 4, 2004:491–504 The Year in Valvular Heart Diseaseithout AVR in 1, balloon valvuloplasty in 1, and medical
herapy in the remaining patients. There were five in-
ospital deaths; at 30 days, the survival rate was 76%. The
nvestigators concluded that nitroprusside could be used
ffectively in severe AS.
OMMENT The concerns are: 1) The single most important
oal and primary end point was an increase in cardiac index
measured by the Fick principle). However, the body oxygen
onsumption (V˙O2) for calculation of cardiac output (CO)
igure 2. The normal aortic valve surface is thin and intact, with a smooth
acrophages or proliferation (C1, D1). On a cholesterol diet, foam cells c
ormed and is stained blue (B2), foam cells stained positive for macrophage
ntigen staining (D2). Animals on a cholesterol diet and treated with atorva
n only the cholesterol diet (A2–D2). (From Rajamannan NM, et al., refas not measured (G. Francis, personal communication, July T, 2003; copy of letter submitted to Editor in Chief) but was
btained from a nomogram of V˙O2 of “normal” people at
est, which is probably not accurate for those in heart failure
nd also may not be the same before and after nitroprusside.
s a consequence, all calculated values of CO, stroke
olume, and systemic vascular resistance are suspect. 2)
here was only a small reduction of PA wedge pressure. 3)
atients were not given diuretics or digitalis but were given
eta-blockers. 4) Mean arterial pressure was reduced. 5)
thelial layer in the spongiosa layer of the valve (A1, B1) and there are no
ged to form a large lipid-laden lesion on the valve leaflet (A2), collagen is
, and there is a marked increase in myofibroblast proliferation cell nuclear
had a marked decrease (A3–D3) in the abnormal findings seen in animals
rints of the figure were provided by Dr. Rajamannan.endo
onver
(C2)
statin
. 3.) Phe numbers of patients who had coronary arteriography
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The Year in Valvular Heart Disease February 4, 2004:491–504nd had significant obstructive coronary artery disease
CAD) were not provided. In this age group, 50% of
atients can be expected to have associated CAD.
OW GRADIENT AORTIC STENOSIS WITH DEPRESSED LV
YSTOLIC FUNCTION. To determine the severity of valve
bstruction in low gradient AS with depressed LV systolic
unction, selected patients with echocardiographic/Doppler
VA 1.0 cm2, mean AV gradient 40 mm Hg, and
VEF 0.40 underwent dobutamine infusion in the car-
iac catheterization laboratory (16). Twenty-one patients
ad AVR, and their outcome was evaluated in two sub-
roups on basis of an increase of stroke volume of 20%
“contractile reserve”). Following AVR, 12 of 15 patients
80%) with “contractile reserve” were in New York Heart
ssociation (NYHA) functional class I and II; 2 of 6 (33%)
ithout “contractile reserve” were in NYHA functional class
and II.
The investigators concluded: “In patients with left ven-
ricular systolic dysfunction and aortic stenosis with a low
utput and low mean gradient, dobutamine challenge may
id in selecting those who would benefit from an aortic valve
peration.”
OMMENT. It is questionable whether changes in stroke
olume should be labeled as an index of contractility.
ecisions for AVR were made by individual clinicians, and
ne patient with “mild” AS had AVR. This was an elegant
igure 3. Possible mechanism for the development of aortic valve calcifica
mportant bone matrix proteins involved in the calcification process in the
y Dr. Rajamannan.tudy in the catheterization laboratory. This study (16) whows that the cause(s) of this clinical syndrome is multi-
actorial because of baseline patient characteristics such as
ypertension, very high left atrial (LA) pressure, mitral
egurgitation (MR), and other factors. For example: 1) the
atient shown in the investigators’ Figure 2A (16) was very
ypertensive, and dobutamine produced a decline in arterial
ressure and a marked increase in CO; 2) the patient in
igure 2B: with dobutamine there was a marked increased
n arterial and LV pressure with little increase of CO; and 3)
he patient in Figure 2C had very high LV end-diastolic
ressure, high LA pressure with marked “v” waves, which
ncreased further with dobutamine. This study shows do-
utamine may have complex effects, and the findings of
hanges in mean aortic valve gradient, and perhaps even in
VA, may be misleading if all the hemodynamic data are
ot carefully analyzed in detail.
EVERE AORTIC STENOSIS WITH SEVERE PULMONARY HY-
ERTENSION (PHTN). A total of 37 patients with severe AS
AVA  1.0 cm2) had severe PHTN (Doppler systolic
ressure 78.8) of whom 86% underwent AVR (17). The
perative mortality was 16% and the five-year survival was
8%, which is most encouraging, but their survival rates are
ompared only to age- and gender-matched patients in the
opulation.
OMMENT. This is a small but important subgroup of
atients with severe AS. The data in patients who under-
The cell within the valve develops osteoblast-like features that synthesize
(From Rajamannan NM, et al., ref. 4.) Prints of the figure were providedtion.
valve.ent AVR are important and interesting (18), but compar-
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February 4, 2004:491–504 The Year in Valvular Heart Diseaseson to the population is of dubious clinical value. It is not
bvious why 10 patients did not have AVR; many probably
ad the phenomenon of “excessive hypertrophy” (19). Not
erforming coronary arteriography is called “reasonable”
20); however, considering the patients’ ages and associated
isk factors it is highly likely50% of patients may have had
ignificant CAD. Severe AS  CAD may have caused
igure 4. Shown are the relationships between degenerated myocytes and
brosis and left ventricular end-diastolic pressure (LVEDP) (C), and chan
f patients. (From Hein S, et al., ref. 10.)
igure 5. A suggested pathway from hypertrophy to failure in AS 
ndocarditis. (From Hein S, et al., ref. 10.) Devere LV diastolic dysfunction. With AVR  CABG,
any could have had a “good” outcome. Note that they had
evere AS plus normal or good LVEF. Important question:
as survival statistically significantly better with AVR 
enticular ejection fraction (EF) (A), fibrosis and left ventricular EF (B),
left ventricular EF after aortic valve replacement (D) in the three groups
igure 6. Relationship between aortic valve area measured by cardiac
atheterization (EOAcath) and energy loss (ELCO). See text. (From Garcialeft v
ges in, et al., ref. 11.)
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The Year in Valvular Heart Disease February 4, 2004:491–504ABG than with medical therapy? (18). Answer not
rovided! (20).
ORTIC REGURGITATION
atural history of rheumatic AR. A total of 75 patients
ith rheumatic AR were evaluated clinically every six
onths and had noninvasive tests at annual intervals (21);
7 patients (49%) became symptomatic within 4.6  1.0
ears (mean age at entry into study was 32  11 years) and
ere scheduled for AVR within six months; one patient
efused surgery, and two died awaiting surgery. After AVR,
0-year survival was 82% (excluding two deaths awaiting
urgery). The follow-up of asymptomatic patients (mean
ge at entry into study was 25 5 years) was 10 0.4 years
Table 2).
OMMENT. Subjects in the asymptomatic group were
ounger at time of entry into the study. At end of follow-up,
his group had large LVs and had a decline in LVEF (Table
). It is likely they may soon become symptomatic and/or
evelop LV dysfunction. An important finding was the time
rom carditis to symptoms, about 30 years.
ITRAL STENOSIS (MS)
itral valve area and dobutamine. The CO by echocar-
iography/Doppler was used to separate patients with MS
ho increased CO with dobutamine by50% (group I: n
able 1. Theoretical Values of Doppler-Derived Effective Orifice
ortic Diameters
Catheter-Derived
EOA (cm2)*
Aortic Diameter  2.0 cm
(AA  3.14 cm
2)
1.50 (1.69) 1.02
1.00 (1.13) 0.76
0.75 (0.85) 0.61
0.50 (0.56) 0.43
The EOA value in parentheses was calculated from the Gorlin equation with the u
EOA  effective orifice area; AA  cross-sectional area of the aorta.
Table 2. Data on Asymptomatic Patients With
Remain
Asymptom
No. of patients 138
Rheumatic etiology 94%
Age at diagnosis (yrs)* 5.8  4
Age at entry into study (yrs) 25  5
Duration of follow-up (yrs) 10  0
LVEDD (mm) baseline 69  9
Final 71  6
LVESD (mm) baseline 45  5
Final 48  4
LVEF (Baseline) 0.64  0
LVEF (Final) 0.59  0
*Whether due to rheumatic carditis or to aortic regurgitation
F, et al., ref. 21.
LVEDD  left ventricular end-diastolic diameter; LVE
end-systolic diameter.7) and by 50% (group II: n  30). The MVA by
lanimetry increased by 10.6  2% (p  0.0001) in group
patients and by 10.7  3% (p  0.0035) in group II
atients. Increases in MVA by pressure half-time were
uch larger (22). The investigators concluded that planim-
try of MVA by echocardiography/Doppler was indepen-
ent of variations in flow.
unctional tricuspid regurgitation (TR) often resolves
fter catheter balloon commissurotomy (CBC) for MS.
eventy-one of 265 patients who underwent CBC for MS
ad moderate to severe TR. Up to 29 months follow-up
howed TR was resolved in 1/15 patients (6.7%) of those
ith unsuccessful long-term CBC result but was resolved in
2/56 patients (39%) of those with successful long-term
BC result (p  0.05) (23).
ardiac events are common in pregnant women with
heumatic MS. Seventy-seven percent of 74 women who
ad 80 pregnancies were non-Caucasians in this study (24);
5% of pregnancies were associated with maternal cardiac
omplications; and fetal and/or neonatal events occurred in
0%. Multivariate independent predictors of an event were
oderate or severe MS with odds ratio (OR) of 3.4 (1.2 to
0.0) and history of cardiac events before pregnancy with
R of 6.8 (1.8 to 25.9).
pen mitral commissurotomy (OMC) as alternative to
BC. A total of 276 symptomatic patients with a mean age
f 30 years, MVA 0.52 cm2, underwent OMC instead of
as for Given Catheter-Derived Effective Orifice Areas and
oppler-Derived EOA (cm2)
Aortic Diameter  3.0 cm
(AA  7.07 cm
2)
Aortic Diameter  4.0 cm
(AA  12.6 cm
2)
1.24 1.34
0.88 0.93
0.68 0.71
0.47 0.48
constant of 44.3. From Garcia D, et al., ref. 11.
eumatic Aortic Regurgitation
Became
Symptomatic
37
91%
5.8  2.1
32  11 p  0.001
4.6  1.0
76  9 p  0.05
51  8 p  0.05
0.60  0.05
stated. †p  0.05 versus baseline. Adapted from Tarasoutchi
eft ventricular ejection fraction; LVESD  left ventricularAre
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February 4, 2004:491–504 The Year in Valvular Heart DiseaseBC because of contraindications to or failed CBC (25). At
0 days there were no early deaths in isolated OMC; three
atients needed reoperation. At hospital discharge, MVA
as 2.6  0.6 cm2. At 130 months there were no late
eaths; five patients needed reoperation, and 91.6% were in
YHA functional class I or II. In operative survivors,
reedom from “mitral valve failure” at 10 years was 87.0%. In
atients with isolated OMC, the thromboembolism rate
as 0.5% per patient-year. The CBC procedure is the
rocedure of first choice for severe MS if the score of the
V is low, there is no thrombus in the LA, MR is absent
r is 2/4 in severity, and commissural calcium is absent or
s restricted to one commissure (26). In two studies, patients
ho had a “good” immediate result, the 7- and 10-year
vent-free survival was, respectively, 90  6% and 61  5%
26). If CBC is not available, OMC is the procedure of
hoice.
ITRAL REGURGITATION
yocardial proinflammatory cytokine expression.
lasma tumor necrosis factor-alpha (TNF-) and its recep-
ors were measured in patients with MR before and after
V repair (MVrep). The main findings were: “1) TNF-
xpression is increased both in the myocardium and plasma
f patients with chronic MR; 2) there is a relationship
etween the extent of LV dilatation and TNF- expression;
) correction of the LV volume overload state with MV
epair leads to reversal of TNF- expression; and 4) the
xtent of regression in the LV remodeling, i.e., reverse LV
emodeling after MVrep, is proportionate to the amount of
reoperative TNF- expression” (27).
lasma natriuretic peptide (NP) levels are elevated in
R. Atrial and brain plasma natriuretic peptides (ANP
nd BNP) were measured in 49 patients with MR (28). The
Ps rose with increasing severity of MR and increases of
A dimensions (p  0.001). The NPs in symptomatic
atients were greater than in asymptomatic patients (p 
.001) and greater in asymptomatic patients with MR than
n normal controls (p 0.0001); NPs did not correlate with
V dimensions or LVEF.
he sympathetic nervous system is activated in MR.
alculated extravascular norepinephrine release rates (NE2)
ere greater in patients with MR than in controls (p 
.007) (29). The NE2 levels were increased in patients with
R who were in clinical class I (p  0.05), or had a mean
A wedge pressure 12 mm Hg (p  0.05), or had LVEF
0.60 (p  0.06). Mean NE2 values were increased further
n patients who had an LVEF 0.60 (p  0.02).
CE inhibitor and beta-blockers in experimental MR.
itral regurgitation was created in 11 closed-chest dogs
30). Both MR and LV were assessed at three, six, and nine
onths. Lisinopril 20 mg/day was started at three months
nd given for the next six months (i.e., until end of study);
tenolol up to 100 mg/day was added at six months and was
iven for the next three months. Atenolol had a beneficial Sffect on MR, LV forward stroke volume, and on LV
nd-systolic stiffness constant (an index of myocardial con-
ractility); these effects were not seen with lisinopril. Lisin-
pril reduced LV end-diastolic pressure and PA wedge
ressure; the addition of atenolol brought about further
eductions in both of these parameters.
OMMENT. Previous experimental studies of MR have
ailed to show an increase of ACE activity in the myocar-
ium and the peripheral vessels (31,32); also, ACE inhibitor
herapy did not reduce MR (30,31). Note that the previ-
usly cited study (30) documented increased levels of NE2
n patients with MR.
iming of surgery in MR. Otto (33) has highlighted
everal controversial issues. She stated:
a) Mitral valve surgery based on Doppler criteria alone is
not appropriate.
b) Utility and timing of surgery for secondary MR
remains controversial.
c) In patients with MR and atrial fibrillation, concurrent
atrial procedure to restore sinus rhythm likely will
become used more widely and likely will be a standard
adjunct to MVrep in the future.
d) In patients with severe MR and LVEF 0.30 or
end-systolic dimension 55 mm, surgery should only
be considered if it is highly likely that MVrep can be
performed.
ITRAL VALVE REPAIR
ong-term follow-up in nonrheumatic and rheumatic
R. Carpentier’s techniques were used in the first 162
atients who underwent MVrep between 1970 and 1994,
0% of whom had “degenerative” MV. Patients had a mean
ge of 56 years; NYHA functional class II or III was present
n 91% (34). Operative mortality was 1.9%. The median
ollow-up was 17 years (range, 1 to 29 years); all patients
xcept one were in NYHA functional class I and II.
urvival, cardiac event-free survival, and reoperation rates
re shown in Figure 7.
From 1970 to 1994, a total of 951 patients with rheu-
atic MR were operated on with reconstructive techniques
laborated by Carpentier. Mean age was 25.8 years; sinus
hythm was present in 63%. Operative mortality was 2%.
ean follow-up was 12 years (maximum, 29 years). Survival
nd reoperation rates are shown in Figure 8 (35).
OMMENT. Although MVrep had been performed in the
950s and 1960s (36), current MVrep techniques and
nthusiasm had their foundation as very good operative
rocedures when described by Alain Carpentier in the early
970s (37,38). The above two studies present excellent
utcome data of MVrep by Carpentier that dates back to
970.
itral valve repair for MR in the United States. The
ociety of Thoracic Surgeons National Cardiac Database
s
a
a
3
M
t
N
I
f
i
e
a
c
s
C
(
R
c
e
9
b
d

w
o
r
m
n
a
(
C
f
P
A
a
F
r
F
r
498 Rahimtoola JACC Vol. 43, No. 3, 2004
The Year in Valvular Heart Disease February 4, 2004:491–504hows that the performance of MVrep in 1990 was 23.2%
nd in 1999 had increased to 32.0%, p  0.0001 (39).
The proportion of patients undergoing MVrep in 1999
nd 2000 (39) decreased with age (41.2% in patients 20 to
9 years, 36.1% in patients 70 years, p  0.0016). The
Vrep was performed more commonly in males (43.5%)
han in females (32.0%), p  0.0001, less commonly as
YHA functional class increased (class I, 47.8% vs. class
V, 33.2%) and for emergent operative status (33.2%) versus
or elective/urgent (38.5%); p value for both  0.0001.
The investigators concluded that the national MVrep rate
s low (42.4%), even between 1999 and 2000 (39), and the
xpected rate should be at least 74%. They observed: “To
pproach this standard it may behoove the cardiac surgical
ommunity to adopt a more formal approach to educating
urgeons in these techniques” (40).
OMMENT. In Paris, France, the incidence of MVrep is90%
40). Thus, the investigators’ estimate of 74% may be too low.
ecurrence of MR after MVrep for MR. A total of 242
onsecutive patients underwent MVrep for “degenerative dis-
igure 8. Actuarial survival after mitral valve (MV) repair of patients wit
igure 7. Survival at 10 and 20 years and freedom from cardiac death (left
egurgitation. (From Braumberger E, et al., ref. 34.)eoperation after MV repair of patients with rheumatic MR is shown in rightase.” Hospital mortality was 1.7%. At eight years, survival was
0.9%; freedom from reoperation was 94.2%; freedom from
leeding and thromboembolic events was 90.4%. The inci-
ence of severe MR (grade2/4) was 1.7% at one month, 17.2
3.8% at five years, and 28.3% at seven years. In patients
ithout “adequate surgical techniques (chordal shortening, use
f annuloplasty ring or sliding plasty)” linearized recurrence
ate of severe MR was 2.5% per year (41).
The researchers concluded: “The durability of successful
itral reconstruction for degenerative mitral valve disease is
ot constant, and this should be taken into account when
symptomatic patients are offered early mitral valve repair”
41).
OMMENT. This was a careful long-term study containing
requent echocardiographic/Doppler studies.
ROSTHETIC HEART VALVES
ortic valve replacement in a conscious patient. A man
ge 70 years with AS, no significant CAD, or hypertension
umatic mitral regurgitation (MR) is shown in left panel. Freedom from
l). Reoperations according to leaflet prolapse (right panel). MR  mitralh rhepanepanel. (From Chauvand S, et al., ref. 35.)
h
a
c
u
T
h
r
s
r
v
(
E
a
t
c
p
C
m
w
E
r
i
T
T
e
e
v
i
t
C
m
m
f
d
s
p
a
t
D
A
b
4
E
fi
P
c
w
r
t
s
F
1
C
P
e
l
p
C
i
T
i
s
t
o
a
t
t
9
s
T
R
t
n
b
V
3
7
t
f
w
0
C
T
S
V
A
499JACC Vol. 43, No. 3, 2004 Rahimtoola
February 4, 2004:491–504 The Year in Valvular Heart Diseasead AVR under regional anesthesia using a number of
nalgesic and sedative agents (42). There was no endotra-
heal intubation, and the postoperative course was
neventful.
issue-engineered heart valve (TEHV). Three studies
ave described efforts to develop TEHV. These consisted of
eseeding in the following ways: 1) with human marrow
tromal cells on the trileaflet heart valves fabricated from
apidly absorbable polymers (43); 2) cultivated human
enous endothelial cells onto cadaver human allografts
homografts) that had been preserved in antibiotic-enriched
arle’s medium 1999 and then decellularized (44); and 3)
ortic valve interstitial cells to repopulate aortic valve leaflets
hat had been decellularized aortic valve leaflets (45). These
onstructed valves showed morphological and mechanical
roperties similar to human native heart valves.
OMMENT. The development of TEHV for valve replace-
ent in humans shows promise. Imagine the possible benefits
hen cardiac valves are developed from human stem cells.
dinburgh heart valve trial. A total of 541 patients were
andomized from 1975 to 1979 to receive either a mechan-
cal valve or a bioprosthesis. Their mean age was 53.9 years.
he major findings at 20 years [% (SEM)] are shown in
able 3 (46). There were no statistically significant differ-
nces for all embolism, major embolism, or endocarditis
vents. The investigators concluded: “Survival with an intact
alve is better among patients with the Bjork-Shiley spher-
cal tilting disc prosthesis than with a porcine prosthesis but
here is an attendant increased risk of bleeding.”
OMMENT. The only other “large” randomized trial of a
echanical valve versus the porcine valve was the Depart-
ent of Veterans Affairs (DVA) trial (47) in which the
ollow-up was 18 years (average, 15 years). The major
ifferences between the two trials are: 1) in the Edinburgh
tudy, the patients were younger and there were more
atients undergoing MVR; 2) in the DVA trial, after AVR
t 15 years the survival was better with a mechanical valve
han with a bioprosthesis (79% vs. 66%, p  0.02); the
VA trial had 87% more patients undergoing isolated
VR; 3) the bleeding rate in the DVA trial was higher
ecause the patients were more heavily anticoagulated; and
able 3. 20-Year Outcome Data From the Edinburgh Heart Val
Aortic Valve Replacem
Mechanical Porcine
urvival
All survivors 28.4 (4.4) 31.3 (4.7)
With original prosthesis 27.5 (4.3) 13.7 (3.6)
Without major event 15.2 (3.5) 8.1 (3.0)
alve-related events
Reoperation 7.4 (3.0) 56.2 (8.4)
All bleeding 61.1 (7.6) 42.4 (12.1)
Major bleeding 37.8 (7.1) 32.0 (12.6)
dapted from Oxenham H, et al., ref. 46.) both trials included rates of all bleeding, but in the tdinburgh trial minor bleeding was not recorded for the
rst five years of the study.
rosthetic heart valve thrombosis (PHVT). A single-
enter study reported on 110 consecutive patients presenting
ith 127 instances of PHVT between 1978 and 2001 and who
eceived fibrinolytic therapy (FT) (48). Full success was ob-
ained in 90/127 instances (70.9%); of 90 instances of full
uccess, 62 (69%) were with a single fibrinolytic agent; multiple
Ts resulted in complete success in another 17% and failure in
2%. Streptokinase and rt-PA fared better than urokinase.
omplications occurred in 32 patients (25.2%) (48–50).
The investigators concluded: “FT is effective in most cases of
HVT, regardless of prosthesis or site involved. However,
mbolism, hemorrhage, and death were not uncommon after
ytic therapy of left-sided PHVT, limiting its application to
atients at high risk with alternative therapy” (48).
OMMENT. Thrombosis of PHV is an uncommon but
mportant complication because it can be life-threatening.
he cited study (48) is a large and important one. Problems
n analysis of results of FT are: 1) patients who initially had
urgery are excluded; 2) patients who are in NYHA func-
ional class I or II have better results than those in class III
r class IV whether patients are treated with surgery or FT;
nd 3) in patients with pannus only or pannus with
hrombus (estimated incidences of 10% and 40%, respec-
ively), it is not likely that FT alone will be successful (Fig.
). Review of previously reported operative mortality of
urgery for PHVT ranged from 10% to 60% (Table 4).
herapeutic suggestions are shown in Table 5.
esults of PHV in nonagenarians. Two studies reported
he results of PHV in nonagenarians. Thirty-five nonage-
arian patients (aged 90 to 100 years old) had PHV
etween 1986 and 2000 and are registered in the UK Heart
alve Registry. The mean age was 91  1.3 years, and
0-day mortality was 17.1%. The two-year survival was
4.3% (women 77.8%, men 70.6%) (51). Twenty-one pa-
ients (AVR in 5; valve  CABG in 16) had PHV surgery
rom 1993 to 2002; their mean age was 91.4 years. There
as no operative mortality. At a mean of 2.53 years (range,
.16 to 7.1 years) after PHV the survival was 81% (52).
OMMENT. In 2000, nonagenarians in the United States
rial
Mitral Valve Replacement
p Value Mechanical Porcine p Value
0.57 22.4 (3.8) 18.4 (3.6) 0.41
0.025 20.8 (3.7) 2.5 (1.4) 0.0001
0.34 11.9 (3.0) 2.5 (1.4) 0.005
0.0001 13.4 (3.9) 77.6 (6.7) 0.0001
0001 53.1 (8.2) 37.2 (10.9) 0.39
0.021 47.3 (8.5) 9.5 (4.1) 0.044ve T
entotaled 1.6 million, and centenarians numbered 72,000; by
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The Year in Valvular Heart Disease February 4, 2004:491–504050, the corresponding numbers are expected to be 8.8
illion and 1.1 million, respectively (52).
atient outcomes with the “small” Carpentier-Edwards
ericardial valve. A total of 94 patients were 75 years of
ge; 28/94 (30%) were women. Valve areas at 14  3.2
onths’ postoperation are shown in Table 6 (53).
Operative mortality was 6.3% and late (12-year) mortality
as an additional 17.2%.
OMMENT. Valve areas cannot be measured with any de-
ree of accuracy to hundredths of a centimeter; thus, the
alculated valve areas should be rounded to the first decimal;
he satisfactory long-term survival of 82.8% (excluding
igure 9. Thrombosed mitral valve in patient in New York Heart Associa
annus (left panel); the removed thrombus is shown in the right panel. Pat
y Dr. Ismael Nuno, LAC  USC Medical Center, Los Angeles, CA.
able 4. Thrombosed Prosthetic Heart Valve
ortality with surgery: 10% to 60%
actors contributing to high mortality:
● NYHA functional classes III or IV and duration in that class
● Severe co-morbid conditions:
Severe clinical heart failure
Severe LV dysfunction
Pulmonary edema
Pulmonary arterial and right atrial hypertension
Very low cardiac output
Multisystem organ failure (renal, hepatic, pulmonary, CNS, and
blood)V  left ventricular; NYHA  New York Heart Association. pperative mortality) in patients age 75 years at the time of
HV was probably because most had mild or moderate
alve prosthesis–patient mismatch; and an earlier study had
hown that patients who received a “small” PHV and had a
ormal LVEF had similar exercise capacity as age- and
ender-matched controls (54).
nctional class IV. View from left atrium shows thrombus on a valve with
ad replacement of the thrombosed valve and is doing well. Figures provided
able 5. Therapeutic Strategies for Prosthetic Heart
alve Thrombosis
ight-sided PHVT
FT is first choice of therapy. If successful, it should be followed by IV
heparin  warfarin until INR appropriate, followed by warfarin
plus low-dose aspirin.
If FT is unsuccessful, surgery.
eft-sided PHVT
● Surgery is first choice for:
pannus and pannus plus thrombus
“large thrombus”
patients in NYHA classes III/IV
unsuccessful FT
● FT is first choice for:
“small” thrombus
patients in NYHA classes I/II
those with severe co-morbid conditions (Table 4)
if surgery is not a viable option
T  fibrinolytic therapy; NYHA  New York Heart Association; PHVT tion fu
ient hrosthetic heart valve thrombosis.
D
C
d
2
p
(
s
c
C
t
r
C
p
(
a
o
f
s
b
C
r
A
b
C

6
4
(
a
4
1
t
A
m
l
C
r
w
d
e
h
o
p
S
t
T
i
1
2
F
v
T
S
U
*
(
m
501JACC Vol. 43, No. 3, 2004 Rahimtoola
February 4, 2004:491–504 The Year in Valvular Heart Diseaseialysis and valve replacement. 1) The STS National
ardiac Surgery Database (55) shows that in patients on
ialysis the operative mortality for PHV is high (Table 7).
) The Renal Dialysis Database (56) showed that in 5,858
atients undergoing PHV the later mortality is very high
Table 7). These investigators concluded: “There is no
ignificant difference in survival of dialysis patients after
ardiac valve replacement in tissue versus non-tissue valves.
urrent practice guidelines proscribing the use of biopros-
hetic heart valves in hemodialysis patients should be
escinded.”
OMMENT. Actually the ACC/AHA Guidelines give bio-
rostheses a class II and not a class III recommendation
57). The important issues are the high operative mortality
nd the very high “early” subsequent mortality. The cause(s)
f mortality was not provided. In patients with less renal
ailure the survival is likely to be better; therefore, the rate of
tructural valve deterioration (SVD) would be expected to
e much higher with use of bioprostheses.
ryopreserved homografts in isolated AVR. Over a pe-
iod of 9.25 years, 164 of 955 (17%) patients undergoing
VR had homograft AVR; 64 patients were excluded
ecause of various reasons including need for predetermined
ABG (58). Of the remaining 100 patients, 24 were aged
40 years, and 70 were aged 40 to 65 years. Twelve- and
0-month survival rates were 100% and 98%, respectively;
5 patients had postoperative morbidity, which included 6
able 6. AVA of “Small” Carpentier-Edwards Pericardial PHV
n Patients Aged 75 Years of Age
PHV
Size n BSA (m2) AVA (cm2)
AVA Index
(cm2/m2)
9 mm 17 1.65  2.0 1.27  0.07 0.78  0.08
1 mm 25 1.69  1.4 1.48  0.03 0.88  0.08
rom Vitale N, et al., ref. 53.
AVA  aortic valve (area); BSA  body surface area; PHV  prosthetic heart
alve.Figure 10. Choice of prosthetic heart valve in adu6%) with acute myocardial infarction, 1 with cardiac arrest,
nd 2 with strokes. Homograft valve-related event rate was
.6% (95% CI, 1.2% to 10.8%) at one year and 5.3% (2% to
3.8%) at five years. The investigators concluded that “given
he superior durability in younger patients, this may be the
VR prosthesis of choice for the young (40 years) to
iddle-aged (40 to 65 years) patient who cannot commit to
ife-long anticoagulation” (58).
OMMENT. The study represented a selected series. The
eported incidence of acute myocardial infarction in those
ithout CAD of 6% was high; follow-up was too short to
etermine incidence of SVD, and there were no serial
chocardiographic/Doppler studies to detect SVD. Note: 1)
omografts are more difficult to insert; need reimplantation
f coronary arteries; 2) they may have a “high” incidence of
erioperative myocardial infarction (58); 3) the incidence of
VD is quite high on longer-term follow-up (59–61); 4)
he SVD deterioration rate is similar to that of bioprostheses
able 7. Valve Replacement in Patients on Renal Dialysis
TS National Cardiac Surgery Database*
Operative Mortality:*
AVR 17.07%
MVR 22.45%
AVR  CABG 24.59%
MVR  CABG 36.89%
.S. Renal Dialysis Database†
Mortality
Whole Group Tissue Valve Nontissue Valve
1 yr 46.0  1.3% 45.3  3.4% 46.0  1.4%
2 yrs 60.4  1.3% 60.3  3.5% 60.3  1.4%
3 yrs 71.9  1.3% 73.8  3.5% 72.8  1.4%
5 yrs 85.2  1.3% 86.2  3.4% 85.1  1.3%
10 yrs 95.6  1.3% 95.6  3.1% 95.7  1.1%
Adapted from Edwards FH, et al., ref. (55). †Adapted from Herzog CA, et al., ref.
56).
AVR  aortic valve replacement; CABG  coronary artery bypass graft; MVR 
itral valve replacement.lt patient. (From Rahimtoola SH, ref. 61.)
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The Year in Valvular Heart Disease February 4, 2004:491–50461,62); and 5) homografts are more expensive than are
ioprostheses!
hoice of PHV for adult patients. The choice of PHV
ased on age is shown in Figure 10 (61). However,
xceptions exist to this general rule. The choice of a PHV
hould be based on several factors, including known long-
erm results from randomized trials and databases, patient
haracteristics such as age, associated cardiovascular, and
ther co-morbid conditions; expected survival of the patient
ased on age and gender, associated cardiovascular and
o-morbid conditions, and known outcomes; unique patient
eeds; complete and accurate discussion and information of
ll of the above with the patient; and joint decision with
atient, cardiologist, and cardiac surgeon.
HVs and pregnancy. In patients with mechanical PHVs,
he incidence of warfarin embryopathy is low (average 3.9%)
ith use of a regimen of intravenous unfractionated heparin
n the first three months (especially between the 6th and
2th week) of pregnancy, and warfarin from week 13 to the
ast two weeks of pregnancy when intravenous unfraction-
ted heparin is again used. Ten studies comprising 427
regnancies reported the incidence was zero; four recent
tudies from 1994 to 1999 reported an incidence of 3/189
1.6%) of live births (62).
Subcutaneous heparin does not improve fetal outcome
nd does increase maternal mortality. The U.S. Food and
rug Administration (FDA) has issued warnings about
he use of low-molecular-weight heparin during preg-
ancy.
Pregnancy in women with bioprostheses is associated
ith SVD; the incidence may average 24% during or
hortly after pregnancy. After bioprosthetic PHV,
he incidence of SVD at 10 years was 55% to 76%;
he incidence of PHV-related reoperation was 60%
o 80%; the mortality rate for reoperation was 3.8% to
.7%.
Algorithms for management of young women with val-
ular heart disease (VHD), those who need PHV, and of
oung women with PHV who become pregnant have been
eveloped (62).
ISCELLANEOUS
rug-related VHD. Pritchett et al. (63) reported three
atients taking pergolide mesylate (Permax, Eli Lilly and
ompany, Indianapolis, Indiana), an ergot-derived dopa-
ine receptor agonist used to treat Parkinson disease and
estless leg syndrome. The patients developed valvular
esions that were strikingly similar to those previously
eported by Connolly et al. (64) in patients taking anorectic
rugs fenfluramine and dexfenfluramine.
eversal of excessive anticoagulation. Novo Seven (Novo
ordisk, Princeton, New Jersey) is a genetically engineered
oncentrate of human coagulation FV-IIa, which is struc-
urally similar to native human plasma-derived FV-IIa.
hirteen patients (only two with VHD) with criticallyincreased INRs” requiring immediate reversal of warfarin-
nduced anticoagulation were given rFV-IIa in doses as low
s 15 to 20 mg/kg intravenously over 3 to 5 min (65). The
NR was immediately reduced after a single infusion. There
ere no adverse effects.
obotic surgery. As part of an FDA trial, MVrep was
erformed in 38 patients using the robotic daVinci surgical
ystem (Intuitive Surgical, Mountain View, California) (66).
here were no “operative deaths,” strokes, or device-related
omplications; one patient died at 20 days. One patient
equired MVR for hemolysis and one was re-explored for
leeding.
re-existing VHD in patients with acute coronary syn-
rome. In the Euro Heart Survey of acute coronary syn-
rome (67), of 10,207 patients with data on VHD, 489
4.8%) had a diagnosis of pre-existing VHD, of whom
4.0% had moderate/severe MR and 31.7% had moderate/
evere AS. Patients with pre-existing VHD had worse
aseline clinical co-morbid conditions and had a more
omplicated in-hospital course. Their OR for adjusted
n-hospital mortality risk ranged from 1.55 to 1.92 depend-
ng on the type of ACS.
eprint requests and correspondence: Dr. Shahbudin H. Ra-
imtoola, University of Southern California, 2025 Zonal Avenue,
os Angeles, California 90033.
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